Nam Tonthat

As genome-edited and multi-edit therapies become more complex, NGS is emerging as a critical tool for product characterization, genome integrity assessment, and safety evaluation. However, translating these methods into a validated, reproducible GMP environment remains a major challenge. Variability across sample preparation, sequencing platforms, and bioinformatics pipelines creates uncertainty about what is truly being measured, while regulatory expectations for validation are still evolving.

Join this workshop to learn more about:

• Building end to end workflows that control variability from sample preparation through sequencing
• Selecting sequencing approaches that align with analytical goals while managing trade-offs in accuracy and coverage
• Validating bioinformatics pipelines to meet regulatory expectations for reproducibility and data integrity
• Applying NGS to improve understanding of genome integrity and complex product composition